Methods for diagnosing and predicting miscarriage in humans by quantitating serum levels of soluble programmed cell death ligand-1 (U.S file Application Re: No 63/518,903)

Fibrosis biomarkers for non-alcoholic fatty liver disease (PCT/IB2021/054808).

Adiponectin-expressing regulatory t-cell precursors, composition and methods thereof (US16/864,774).

Use of secreted CDCP1 for improved treatment of nonalcoholic steatohepatitis (U.S file Application Re: No 63/578,888).

Application of monoclonal A-FABP antibody for the treatment of ischemic stroke. (CN patent filed number: 202211439397.5; European patent filed number: EP23209441 and US patent filed No. 18/506,988).

Methods and compositions for use of neutrophil elastase and proteinase 3 as diagnostic biomarkers (WIPO (PCT) number: WO2015180687A1)

Methods and Compositions for use of Neutrophil Elastase and Proteinase 3 as Diagnostic Markers (US patent number: US9625460B2).

Non-polyaminated lcn2 as a biomarker for diagnosis and treatment of cardiometabolic diseases (WIPO (PCT) number: WO2018076284A1)

Inhibitors of fabp4 and methods of treating arthritis (WIPO (PCT) number: WO2018192469A1)

Lipocalin-2 antibodies for methods of treatments. (US patent number: 8,481,032B2)

Lipocalin-2 as a prognostic and diagnostic marker for heart and stroke risks. (US patent number: 8,030,097 B2)

Phosphoprotein target for insulin and insulin antagonists. (US patent number: US 6,884,575)

Adiponectin and uses thereof. (US patent Number: 7,365,170)

Lipocalin-2 as a diagnostic marker and therapeutic target. (US patent No: 7,645,616.)